A gain of function TGFB1 polymorphism may be associated with late stage prostate cancer

Cancer Epidemiology Biomarkers and Prevention

Volumn 13, Issue 5, 2004, Pages 759-764

  Ewart Toland, Amanda ^a   Chan, June M ^b   Yuan, Jinwei ^a   Balmain, Allan ^a,b   Ma, Jing ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ISOPROTEIN; TRANSFORMING GROWTH FACTOR BETA;

ADULT; AGED; ALLELE; ARTICLE; CANCER RISK; CARCINOGENESIS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DNA POLYMORPHISM; GENE; GENE EXPRESSION; GENE FREQUENCY; GENE LINKAGE DISEQUILIBRIUM; GENETIC VARIABILITY; HUMAN; MALE; METASTASIS; PRIORITY JOURNAL; PROGNOSIS; PROSTATE CANCER; RANDOMIZED CONTROLLED TRIAL; TGFB1 GENE; TUMOR PROMOTION;

ADULT; AGE DISTRIBUTION; AGED; ALLELES; CASE-CONTROL STUDIES; CONFIDENCE INTERVALS; GENETIC MARKERS; GENETIC PREDISPOSITION TO DISEASE; HUMANS; INCIDENCE; LOGISTIC MODELS; MALE; MIDDLE AGED; NEOPLASM STAGING; ODDS RATIO; POLYMORPHISM, GENETIC; POLYMORPHISM, RESTRICTION FRAGMENT LENGTH; PROBABILITY; PROSTATIC NEOPLASMS; REFERENCE VALUES; RISK ASSESSMENT; SENSITIVITY AND SPECIFICITY; TRANSFORMING GROWTH FACTOR BETA;

EID: 2942608991     PISSN: 10559965     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (33)

1. Derynck R, Akhurst RJ, Balmain A. TGF-β signaling in tumor suppression and cancer progression. Nat Genet 2001;29:117-29.
2. Cui W, Fowlis DJ, Bryson S, et al. TGFβ1 inhibits the formation of benign skin tumors, but enhances progression to invasive spindle carcinomas in transgenic mice. Cell 1996;86:531-42.
3. Wakefield LM, Yang YA, Dukhanina O. Transforming growth factor-β and breast cancer: lessons learned from genetically altered mouse models. Br Cancer Res 2000;2:100-6.
4. Timme TL, Truong LD, Merz VW, et al. Mesenchymal-epithelial interactions and transforming growth factor-β expression during mouse prostate morphogenesis. Endocrinology 1994;134:1039-45.
5. Truong LD, Kadmon D, McCune BK, Flanders KC, Scardino PT, Thompson TT. Association of transforming growth factor-β1 with prostate cancer: an immunohistochemical study. Hum Pathol 1993;24:4-9.
6. Steiner MS. Transforming growth factor-β and prostate cancer. World J Urol 1995;13:329-36.
7. Wikstrom P, Damber J-E, Bergh A. Role of transforming growth factor-b1 in prostate cancer. Microsc Res Technol 2001;52:411-9.
8. Bello-DeOcampo D, Tindall DJ. TGF-β/Smad signaling in prostate cancer. Curr Drug Targets 2003;4:197-207.
9. Eastham JA, Truong LD, Rogers E, et al. Transforming growth factor-β 1: comparative immunohistochemical localization in human primary and metastatic prostate cancer. Lab Invest 1995;73:628-35.
10. Ivanovic V, Melman A, Davis-Joseph B, Valcic M, Geliebter J. Elevated plasma levels of TGFβ-1 in patients with invasive prostate cancer. Nat Med 1995;1:282-4.
11. Wikstrom P, Stattin P, Franck-Lissbrant I, Damber JE, Bergh A. Transforming growth factor β1 is associated with angiogenesis, metastasis, and poor clinical outcome in prostate cancer. Prostate 1998;37:19-29.
12. Shariat SF, Shalev M, Menesses-Diaz A, et al. Preoperative plasma levels of transforming growth factor β(1) (TGF-β(1)) strongly predict progression in patients undergoing radical prostatectomy. J Clin Oncol 2001;19:2856-64.
13. Perry KT, Anthony CT, Case T, Steiner MS. Transforming growth factor β as a clinical biomarker for prostate cancer. Urology 1997;49:151-5.
14. Yokota M, Ichihara S, Lin TL, Nakashima N, Yamada Y. Association of a T29-C polymorphism of the transforming growth factor β-1 gene with genetic susceptibility to myocardial infarction in Japanese. Circulation 2000;101:2783-7.
15. Grainger DJ, Heathcote K, Chiano M, et al. Genetic control of the circulating concentration of transforming growth factor type 1. Hum Mol Genet 1999;8:93-7.
16. Dunning AM, Ellis PD, McBride S, et al. A transforming growth factor β1 signal peptide variant increases secretion in vitro and is associated with increased incidence of invasive breast cancer. Cancer Res 2003;63:2610-5.
17. Ziv E, Cauley J, Morin PA, Saiz R, Browner WS. Association between the T29-C polymorphism in the transforming growth factor b1 gene and breast cancer among elderly white women. The study of osteoporotic fractures. JAMA 2001;285:2859-63.
18. Syrris P, Carter ND, Metcalfe JC, et al. Transforming growth factor-β 1 gene in relation to myocardial infarction and blood pressure. The Etude Cus-Termain de l'Infarctus du Myocarde (ECTIM) Study. Hypertension 1996;28:881-7.
19. Chan JM, Stampfer MJ, Ma J, et al. Insulin-like growth factor-I (IGF-I) and IGF binding protein-3 as predictors of advanced-stage prostate cancer. J Natl Cancer Inst 2002;94:1099-106.
20. Hennekens CH, Buring JE, Manson JE, et al. Lack of effect of long-term supplementation with β carotene on the incidence of malignant neoplasms and cardiovascular disease. N Engl J Med 1996;334:1145-9.
21. Zheng S, Ma X, Buffler PA, Smith MT, Wiencke JK. Whole genome amplification increases the efficiency and validity of buccal cell genotyping in pediatric populations. Cancer Epidemiol Biomarkers & Prev 2001;10:697-700.
22. Devlin B, Risch N. A comparison of linkage disequilibrium measures for fine-scale mapping. Genomics 1995;29:311-22.
23. Ohtsuka T, Yamakage A, Yamazaki S. The polymorphism of transforming growth factor-β1 gene in Japanese patients with systemic sclerosis. Br J Dermatol 2002;147:458-63.
24. Crilly A, Hamilton J, Clark CJ, Jardine A, Madhok R. Analysis of transforming growth factor β1 gene polymorphisms in patients with systemic sclerosis. Ann Rheum Dis 2002;61:678-81.
25. Rosmund R, Chagnon M, Bouchard C, Bjorntorp P. Increased abdominal obesity, insulin and glucose levels in nondiabetic subjects with a T29C polymorphism of the transforming growth factor-β(1) gene. Horm Res 2003;59:191-4.
26. Pulleyn LJ, Newton R, Adcock IM, Barnes PJ. TGFβ1 allele association with asthma severity. Hum Genet 2001;109:623-7.
27. Holweg CT, Baan CC, Niesters HG, et al. TGF-β1 gene polymorphisms in patients with end-stage heart failure. J Heart Lung Transplant 2001;20:979-84.
28. Yamada Y, Okuizumi H, Miyauchi A, Takagi Y, Ikeda K, Harada A. Association of transforming growth factor β1 genotype with spinal osteophytosis in Japanese women. Arthritis Rheum 2000;43:452-60.
29. Hinke V, Seck T, Clanget C, Scheidt-Nave C, Ziegler R, Pfeilschifter J. Association of transforming growth factor-β1 (TGFβ1) T29 → C gene polymorphism with bone mineral density (BMD), changes in BMD, and serum concentrations of TGF-β1 in a population-based sample of postmenopausal German women. Calcif Tissue Int 2001;69:315-20.
30. Hishida A, Iwata H, Hamajima N, et al. Transforming growth factor B1 T29C polymorphism and breast cancer risk in Japanese women. Br Cancer 2003;10:63-9.
31. Sugiura Y, Niimi T, Sato S, et al. Transforming growth factor b1 gene polymorphism in rheumatoid arthritis. Ann Rheum Dis 2002;61:826-8.
32. Blagosklonny MV. A node between proliferation, apoptosis, and growth arrest. BioEssays 1999;21:704-9.
33. Pelengaris S, Khan M, Evan G. c-MYC: More than just a matter of life and death. Nat Rev Cancer 2002;2:764-76.